Lipids, blood pressure and kidney update 2014

被引：77

作者：

Banach, Maciej ^{[1
]}

Aronow, Wilbert S. ^{[2
]}

Serban, Corina ^{[3
]}

Sahebkar, Amirhossein ^{[4
,5
]}

Rysz, Jacek ^{[1
]}

Voroneanu, Luminita ^{[6
,7
]}

Covic, Adrian ^{[6
,7
]}

机构：

[1] Med Univ Lodz, Dept Hypertens, Chair Nephrol & Hypertens, Zeromskiego 113, PL-90549 Lodz, Poland

[2] New York Med Coll, Dept Med, Valhalla, NY 10595 USA

[3] Victor Babes Univ Med & Pharm, Discipline Pathophysiol, Dept Funct Sci, Timisoara, Romania

[4] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Iran

[5] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Metab Res Ctr, Perth, WA 6009, Australia

[6] CI Parhon Univ Hosp, Nephrol Clin, Dialysis & Renal Transplant Ctr, Iasi, Romania

[7] Grigore T Popa Univ Med & Pharm, Iasi, Romania

来源：

PHARMACOLOGICAL RESEARCH | 2015年 / 95-96卷

关键词：

Blood pressure; Cholesterol; Dyslipidemia; Hypertension; Lipids; Renal disease; Statin intolerance statin myopathy; EXPERT CONSENSUS DOCUMENT; PCSK9; MONOCLONAL-ANTIBODY; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; CHRONIC RENAL-DISEASE; CHOLESTEROL HDL-C; CARDIOVASCULAR RISK; FAMILIAL HYPERCHOLESTEROLEMIA; HYPERTENSIVE PATIENTS; DYSFUNCTIONAL-HDL;

D O I：

10.1016/j.phrs.2015.03.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This paper is an effort to review all the most important studies and guidelines in the topics of lipid, blood pressure and kidney published in 2014. Irrespective of advances, the options for improving simultaneous hypercholesterolemia and hypertension management (as well as its complication - chronic kidney disease) remain a problem. Recommending hypolidemic, hypotensive and kidney disease drugs to obtain therapy targets in cardiovascular, diabetic, elderly and kidney disease (=high risk) patients might strengthen risk factor control, improve compliance and the therapy efficacy, and in the consequence reduce the risk of cardiovascular events and mortality rate. That is why the authors have decided to summary and discuss the recent scientific achievements in the field of lipid, blood pressure and kidney. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：111 / 125

页数：15

共 180 条

[1] The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass [J].

Adluri, Rajeshwara Krishna Prasad ;

Singh, Arvind V. ;

Skoyles, Julian ;

Robins, Adrian ;

Hitch, Anthony ;

Baker, Mya ;

Mitchell, Ian Moore .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 35 (06) :988-994

[2] Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].

Agodoa, LY ;

Appel, L ;

Bakris, GL ;

Beck, G ;

Bourgoignie, J ;

Briggs, JP ;

Charleston, J ;

Cheek, D ;

Cleveland, W ;

Douglas, JG ;

Douglas, M ;

Dowie, D ;

Faulkner, M ;

Gabriel, A ;

Gassman, J ;

Greene, T ;

Hall, Y ;

Hebert, L ;

Hiremath, L ;

Jamerson, K ;

Johnson, CJ ;

Kopple, J ;

Kusek, J ;

Lash, J ;

Lea, J ;

Lewis, JB ;

Lipkowitz, M ;

Massry, S ;

Middleton, J ;

Miller, ER ;

Norris, K ;

O'Connor, D ;

Ojo, A ;

Phillips, RA ;

Pogue, V ;

Rahman, M ;

Randall, OS ;

Rostand, S ;

Schulman, G ;

Smith, W ;

Thornley-Brown, D ;

Tisher, CC ;

Toto, RD ;

Wright, JT ;

Xu, SC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728

[3] Statin Intolerance [J].

Ahmad, Zahid .

AMERICAN JOURNAL OF CARDIOLOGY, 2014, 113 (10) :1765-1771

[4] Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation [J].

Akasaki, Y. ;

Matsuda, S. ;

Nakayama, K. ;

Fukagawa, S. ;

Miura, H. ;

Iwamoto, Y. .

OSTEOARTHRITIS AND CARTILAGE, 2009, 17 (02) :235-243

[5] Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation [J].

Alonso, Rodrigo .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (19) :1983-1989

[6]

Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS81, DOI [10.2337/dc13-S067, 10.2337/dc13-S011, 10.2337/dc12-s064, 10.2337/dc14-S081, 10.2337/dc10-S011, 10.2337/dc11-S062, 10.2337/dc12-s011, 10.2337/dc10-S062, 10.2337/dc11-S011]

[7] Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial [J].

Ando, Katsuyuki ;

Ohtsu, Hiroshi ;

Uchida, Shunya ;

Kaname, Shinya ;

Arakawa, Yoshihiro ;

Fujita, Toshiro .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (12) :944-953

[8]

Andres A, 2014, CIRC RES, V115

[9]

[Anonymous], 2012, Kidney Int Suppl (2011), V2, P363

[10]

[Anonymous], 2012, Kidney Int Suppl (2011), V2, P357

← 1 2 3 4 5 6 7 8 9 10 →